IP Library Granted Patent US 7,642,280
Granted Patent B2
US 7,642,280 · App. 10/474,138 · Granted Jan 5, 2010

Inhibitors of acyl glucosaminyl inositol amidase and methods of use

Assignees: The Regents of the University of California; National Institutes of Health
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,642,280
App. No.
10/474,138
Granted
Jan 5, 2010
Kind
B2
Abstract

The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.

Claims (9)

1. A compound having Structure I:

wherein each of x and y independently has the value of 0 or 1, and each of X 1 and X 2 is —O(CH 2 ) m Q, wherein m=1-4 and wherein Q is selected from the group consisting of —NH 2 , —NH(CH 2 ) s CH 3 , —N[(CH 2 ) s CH 3 ] 2 , —N + [(CH 2 ) s CH 3 ] 3 , and —(CH 2 ) s NH 2 , wherein s=0-3, n=1-6, and r=0-4;

W is selected from the group consisting of —H and —OH;

wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is independently selected from the group consisting of —H, —CH 3 , and —(CH 2 ) p CH 3 , wherein p=0-3, R 4 is optionally present and —CHR 2 and R 3 can join to become —C═CR 7 , forming an imidazole ring, and then R 7 is selected from the group consisting of: H,

wherein each of X 5 , X 6 , and X 7 is independently selected from the group consisting of —H, —F, —Cl, —Br, —I, —OH, —OCH 3 , —NH 2 , —CONH 2 and —O(CH 2 ) m Q, wherein m=1-4 and wherein Q is selected from the group consisting of —NH 2 , —NH(CH 2 ) s CH 3 , —N[(CH 2 ) s CH 3 ] 2 , and —N + [(CH 2 ) s CH 3 ] 3 , wherein s=0-3, n=1-6, and r=0-4; and

wherein R 9 is selected from the group consisting of —H, CH 3 , and (CH 2 ) s CH 3 , wherein s=0-3,

and pharmaceutically suitable salts thereof.

2. The compound of claim 1 , having Structure I, wherein m=3, Q is —NH 2 , x=0, y=1, and n=1 or 2.

3. The compound of claim 1 having the chemical structure:

Assignments (4)
CONFIRMATORY LICENSE Recorded Oct 17, 2011
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027074/0098 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Jul 30, 2008
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021312/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2004
From: BEWLEY, CAROLE A.; NICHOLAS, GILLIAN
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 014922/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2004
From: FAHEY, ROBERT C.; NEWTON, GERALD L.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Reel/Frame 014922/0866 →
Continuity (2)
Provisional Application 6028209600 · Apr 6, 2001
Related Publication 20040167331A1 · Aug 26, 2004